Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ampuero J
  • Pais R
  • Aller R
  • Gallego-Durán R
  • Crespo J
  • García-Monzón C
  • Boursier J
  • Vilar E
  • Petta S
  • Ming-Hua Z
  • Escudero D
  • Calleja JL
  • Aspichueta P
  • Diago M
  • Rosales JM
  • Caballería J
  • Gómez-Camarero J
  • Lo Iacono O
  • Albillos A
  • Turnes J
  • Banales JM
  • Ratziu V
  • Romero-Gómez M
  • HEPAmet Registry
  • Agustin S
  • Jorquera F
  • Frances R
  • Garcia-Samaniego J
  • Salmeron J
  • Fernandez-Rodriguez C
  • Estevez P
  • Andrade R
  • Soriano G
  • Fernandez-Bermejo M
  • Arias Loste MT
  • Sigüenza R
  • Giannetti A
  • Del Pozo Maroto E

Grupos

Abstract

Fibrosis affects prognoses for patients with nonalcoholic fatty liver disease (NAFLD). Several non-invasive scoring systems have aimed to identify patients at risk for advanced fibrosis, but inconclusive results and variations in features of patients (diabetes, obesity and older age) reduce their diagnostic accuracy. We sought to develop a scoring system based on serum markers to identify patients with NAFLD at risk for advanced fibrosis.

Datos de la publicación

ISSN/ISSNe:
1542-3565, 1542-7714

Clinical Gastroenterology and Hepatology  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
216-216
PubMed:
31195161
Factor de Impacto:
2,634 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 144

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HOMA, cirrhosis, diagnostic tool, prognostic factor, steatosis

Campos de Estudio

Cita

Compartir